SAPPIENS - Moving forward against Parkinson's

WHO WE ARE.

SAPPIENS is a subsidiary of CXS Therapeutics, our bioinformatics platform dedicated to the identification and development of therapeutic molecules for diseases affecting the central nervous system.

SAPPIENS was created following the identification of a new drug candidate for Parkinson's disease, and aims to carry out the pharmaceutical development of a first therapeutic treatment, CXS003.

CXS website

THE NEED FOR NEUROPROTECTIVE TREATMENT FOR PARKINSON'S DISEASE

10 million people worldwide suffer from Parkinson's disease. It represents a considerable socio-economical cost, a rising incidence and a doubling of prevalence over 25 years and a real burden for caregivers and patients alike.

THE FUNCTION OF CURRENT TREATMENTS

Symptomatic treatments to counteract the neurons' deficient production of dopamine. Duration of action decreases as the disease progresses.

Objectives of current treatments PARKINSON

PARKINSON neuroprotective treatment targets

THE OBJECTIVE OF NEUROPROTECTIVE TREATMENT

Directly reduce the loss of neurons to compensate for the reduced response to symptomatic treatments and slow down the progression to loss of autonomy.

As the WHO points out, "worldwide, disability and mortality attributable to Parkinson's disease are increasing rapidly".

WHO statistics

SAPPIENS AND ITS FIRST CANDIDATE FOR THERAPEUTIC USE : CXS003

A patented, innovative and de-risked solution.

A patent published in 2024 covering CXS003 and its novel combination of molecules.

An innovative treatment restores neuronal viability, expected to have a neuroprotective effect.

De-risked, fast, and low-cost development thanks to proven tolerance.

CXS003 restores
neuronal viability

The use of CXS003 restores neurite neurite length and cell cell viability in an induced model of diseased neurons.

Healthy neurons

Diseased neurons

Diseased neurons + CXS003

The use of a innovative dosage optimizes treatment effect.

*BDNF: brain-derived neurotrophic factor

CXS003, an innovative first program ready to enter phase 2

A NETWORK OF EXCELLENCE
SUPPORTS OUR PROGRAM

Pre-clinical and clinical experts specialized in neurology and Parkinson's disease.

Hospital centers integrating a multidisciplinary research network throughout France.

National and international foundations in the fight against Parkinson's disease, including associations.

OUR TEAM

Clinical and scientific expertise. An operational management board. Key partners recognized for their expertise.

GUILLAUME BRACHET

Chairmanship

Co-founder and board member

Pharmacist - researcher. Expert in pharmaceutical innovation and biomedicines. Diagnosed with Parkinson's disease in 2018.

NADINE MACKENZIE

Medical management

Co-founder and board member

Rheumatologist. Medical Director in the pharmaceutical industry for 20+ years. Former member of the Executive Committee of LEO Pharma France.

ANTHONY ALIOUI

Scientific management

Co-founder and board member

PhD in genetics and molecular physiology. Expert in prevention and health promotion. Founder of the "MS PEDAGO" training organization.

PHILIPPE NUSSBAUMER

Dilutive/non-dilutive financing

Co-founder and board member

Expert in the creation and development of innovative companies. Co-founder of the Early DeepTech investment fund "Valeureux".

DJAMCHID DALILI

Strategy

Co-founder and board member

Ecole Polytechnique and PhD in nuclear physics. Founder of the 3W Academy (developer school). Founder and CEO of MedTech "DiamPark" (Parkinson's).

GABRIELLE GACHE

Licensing/Business development

Board member

C-level Executive from the Pharma-Biotech industry, Advisor and Board Member with 25+ years experience in Corporate and Business Dev., Licensing and Access. President of " Swiss Healthcare Licensing Group "from 2015 to 2022.